Last Updated: August 15, 2026

INVELTYS Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Inveltys, and when can generic versions of Inveltys launch?

Inveltys is a drug marketed by Alcon Labs Inc and is included in one NDA. There are thirteen patents protecting this drug.

This drug has eighty-seven patent family members in thirteen countries.

The generic ingredient in INVELTYS is loteprednol etabonate. There are ten drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Inveltys

A generic version of INVELTYS was approved as loteprednol etabonate by SENTISS on April 17^th, 2019.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for INVELTYS?
What are the global sales for INVELTYS?
What is Average Wholesale Price for INVELTYS?

Summary for INVELTYS

International Patents:	87
US Patents:	13
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INVELTYS

US Patents and Regulatory Information for INVELTYS

INVELTYS is protected by fourteen US patents.

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Labs Inc	INVELTYS	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	210565-001	Aug 22, 2018		RX	Yes	Yes	9,056,057	⤷ Start Trial	Y			⤷ Start Trial
Alcon Labs Inc	INVELTYS	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	210565-001	Aug 22, 2018		RX	Yes	Yes	9,737,491	⤷ Start Trial				⤷ Start Trial
Alcon Labs Inc	INVELTYS	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	210565-001	Aug 22, 2018		RX	Yes	Yes	11,219,597	⤷ Start Trial				⤷ Start Trial
Alcon Labs Inc	INVELTYS	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	210565-001	Aug 22, 2018		RX	Yes	Yes	10,646,437	⤷ Start Trial	Y			⤷ Start Trial
Alcon Labs Inc	INVELTYS	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	210565-001	Aug 22, 2018		RX	Yes	Yes	9,827,191	⤷ Start Trial	Y			⤷ Start Trial
Alcon Labs Inc	INVELTYS	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	210565-001	Aug 22, 2018		RX	Yes	Yes	11,872,318	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for INVELTYS

See the table below for patents covering INVELTYS around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Australia	2013256130		⤷ Start Trial
Australia	2018201772		⤷ Start Trial
Australia	2020203213	PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT	⤷ Start Trial
Canada	2871778	NANOPARTICULES PHARMACEUTIQUES PERMETTANT UN TRANSPORT MUQUEUX AMELIORE (PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT)	⤷ Start Trial
European Patent Office	2844295	NANOPARTICULES PHARMACEUTIQUES PERMETTANT UN TRANSPORT MUQUEUX AMÉLIORÉ (PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT)	⤷ Start Trial
European Patent Office	4008355	NANOPARTICULES PHARMACEUTIQUES PERMETTANT UN TRANSPORT MUQUEUX AMÉLIORÉ (PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT)	⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.